← Every applicant
Upsher Smith Labs FDA Approvals
17 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| PREDNISOLONE ACETATENew drugSep 28, 2026SUSPENSION/DROPS, OPHTHALMIC |
| OSELTAMIVIR PHOSPHATENew drugJan 22, 2026CAPSULE, ORAL |
| CIPROFLOXACIN AND DEXAMETHASONENew drugJan 6, 2026SUSPENSION/DROPS, OTIC |
| DEFLAZACORTNew drugAug 11, 2025SUSPENSION, ORAL |
| BRIMONIDINE TARTRATENew drugJul 30, 2025SOLUTION/DROPS, OPHTHALMIC |
| DIFLUPREDNATENew drugFeb 11, 2025EMULSION, OPHTHALMIC |
| DEFLAZACORTNew drugNov 5, 2024TABLET, ORAL |
| BRIMONIDINE TARTRATENew drugJun 12, 2024SOLUTION/DROPS, OPHTHALMIC |
| VIGABATRINNew drugJun 29, 2023TABLET, ORAL |
| ELIGLUSTAT TARTRATENew drugMay 2, 2023CAPSULE, ORAL |
| BRIMONIDINE TARTRATE AND TIMOLOL MALEATENew drugDec 12, 2022SOLUTION/DROPS, OPHTHALMIC |
| FLUOXETINE HYDROCHLORIDENew drugNov 15, 2022SOLUTION, ORAL |
| FLUPHENAZINE HYDROCHLORIDENew drugOct 24, 2022TABLET, ORAL |
| ISOTRETINOINNew drugSep 21, 2021CAPSULE, ORAL |
| ISOTRETINOINNew drugApr 12, 2021CAPSULE, ORAL |
| DROXIDOPANew drugFeb 18, 2021CAPSULE, ORAL |
| MOXIFLOXACIN HYDROCHLORIDENew drugFeb 10, 2021SOLUTION/DROPS, OPHTHALMIC |